Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning

PLoS One. 2024 Apr 25;19(4):e0290221. doi: 10.1371/journal.pone.0290221. eCollection 2024.

Abstract

The Omicron SARS-CoV-2 variant continues to strain healthcare systems. Developing tools that facilitate the identification of patients at highest risk of adverse outcomes is a priority. The study objectives are to develop population-scale predictive models that: 1) identify predictors of adverse outcomes with Omicron surge SARS-CoV-2 infections, and 2) predict the impact of prioritized vaccination of high-risk groups for said outcome. We prepared a retrospective longitudinal observational study of a national cohort of 172,814 patients in the U.S. Veteran Health Administration who tested positive for SARS-CoV-2 from January 15 to August 15, 2022. We utilized sociodemographic characteristics, comorbidities, and vaccination status, at time of testing positive for SARS-CoV-2 to predict hospitalization, escalation of care (high-flow oxygen, mechanical ventilation, vasopressor use, dialysis, or extracorporeal membrane oxygenation), and death within 30 days. Machine learning models demonstrated that advanced age, high comorbidity burden, lower body mass index, unvaccinated status, and oral anticoagulant use were the important predictors of hospitalization and escalation of care. Similar factors predicted death. However, anticoagulant use did not predict mortality risk. The all-cause death model showed the highest discrimination (Area Under the Curve (AUC) = 0.903, 95% Confidence Interval (CI): 0.895, 0.911) followed by hospitalization (AUC = 0.822, CI: 0.818, 0.826), then escalation of care (AUC = 0.793, CI: 0.784, 0.805). Assuming a vaccine efficacy range of 70.8 to 78.7%, our simulations projected that targeted prevention in the highest risk group may have reduced 30-day hospitalization and death in more than 2 of 5 unvaccinated patients.

Publication types

  • Observational Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 Vaccines / administration & dosage
  • COVID-19* / epidemiology
  • COVID-19* / mortality
  • COVID-19* / virology
  • Comorbidity
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Longitudinal Studies
  • Machine Learning*
  • Male
  • Middle Aged
  • Retrospective Studies
  • SARS-CoV-2* / isolation & purification
  • Vaccination

Substances

  • COVID-19 Vaccines

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

The work was supported by the VA Cooperative Studies Program (all authors) and the VA Palo Alto Healthcare System (S. Nallamshetty, N. Fullenkamp, J. Lee). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.